Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor

Arthritis: sales will hit $24 billion in 2007

Published By Datamonitor

DePuy/BTG: orthopedic powerhouse to drive hyaluronic acid

Published By Datamonitor

UK Arthritis Sufferers Receiving Second Best in Pain Medication

Many rheumatoid and osteoarthritis sufferers in the UK may have to settle for second best in pain medication and are being put at risk of developing serious gastrointestinal side effects (GI) according to market analysts, Datamonitor.

Published By Datamonitor

Amgen: Kineret combination approved across EU

The approval for a Kineret/methotrexate combination for rheumatoid arthritis (RA) patients is a major advance for Amgen, since national formularies across Europe will now list the combination therapy as a valid second-line treatment. The ruling should open up Amgen's market, allowing it to grab market share from other drugs currently used in second-line therapy.

Published By Datamonitor

Merck: the victim of definitions

Merck has been forced to concede ground to its rival Pharmacia over the development of COX-II inhibitors, predominantly used for the relief of signs and symptoms of arthritis. The big pharma has withdrawn its application for Arcoxia's FDA approval - but how severe will the cost of the drug's false start prove?

Published By Datamonitor

Pharmacia: increasing its domination in pain

It's been a busy week for Pharmacia in pain management. Injectable Dynastat has been approved in Europe, while oral Bextra has launched in the US. Both drugs have significant advantages over existing therapies, and they complement each other well. Together, they will help Pharmacia tighten its grip on the $17 billion pain market.

Published By Datamonitor

Rheumatoid arthritis: growing fastest in France

Published By Datamonitor

Arcoxia: a not so Mercky future

The first months of 2002 has seen a number of significant events in the COX-II market, including the launch of Dynastat and Arcoxia in Europe and Bextra's US launch. In an already competitive market, the entry of the second-generation COX-II inhibitors will further heighten the rivalry, so who will prevail?<BR />

Published By Datamonitor

Hyaluronic acid: osteoarthritis patients feel the need

New research finds that in certain European countries and Japan in particular, hyaluronic acid therapy is quite popular among knee osteoarthritis patients who are looking to reduce pain, improve joint mobility, and potentially delay knee surgery. However, a lack of evidence supporting the therapy's effectiveness is holding it back in the US and Europe.

Published By Datamonitor